Deciphering biology,
discovering new anti-infectives

through deep phenotypic insights and machine learning


Discovering new classes of anti-infectives to overcome drug resistant infections.

Our machine learning (ML)-based imaging platform for anti-infective drug discovery enables rapid and highly efficient identification of compounds with new and unexploited mechanisms of action at the very outset of the discovery process.

Our combined expertise, cutting edge technologies and novel workflows enable a rapid and early understanding of a compound’s mechanism of action, the potential addressable target product profile, and clinical utility based on deep analysis of cell behavior.

Explore Platform

Delivering new classes of anti-infectives.

ArrePath is applying its technology platform to develop a pipeline of new classes of antibiotics,
targeting unexploited and under-exploited mechanisms of action, to address unmet clinical need and overcome drug resistance.

Discover Strategy

Recent News and Updates

  • 7th AMR Conference 2023

    We are looking forward to the 7th AMR Conference, March 16-17, Basel, Switzerland, where our CEO, Lloyd Payne and founder Zemer Gitai will be attending.

    Calendar 02-27-2023
  • BioInfect 2023

    ArrePath is looking forward to taking part in BioInfect 2023 on February 1, 2023

    Calendar 01-27-2023
  • ArrePath Default News

    ArrePath Appoints Connor Coley, PhD, and Paul Hergenrother, PhD, to Scientific Advisory Board

    ArrePath today announced that it has appointed two new members to its Scientific Advisory Board (SAB):  Connor Coley, PhD, Henri Slezynger (1957) Career Development Assistant Professor in Chemical Engineering at MIT, and Paul Hergenrother, PhD, Kenneth L. Rinehart Jr. Endowed Chair in Natural Products Chemistry, and Professor of Chemistry at the University of Illinois Urbana-Champaign.

    Calendar 11-18-2022